Abstract
Summary
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided.
LPI (LP Information)' newest research report, the “Antiplatelet Drugs Industry Forecast” looks at past sales and reviews total world Antiplatelet Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Antiplatelet Drugs sales for 2023 through 2029. With Antiplatelet Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiplatelet Drugs industry.
This Insight Report provides a comprehensive analysis of the global Antiplatelet Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiplatelet Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antiplatelet Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiplatelet Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiplatelet Drugs.
The global Antiplatelet Drugs market size is projected to grow from US$ 1410.4 million in 2022 to US$ 1914.2 million in 2029; it is expected to grow at a CAGR of 1914.2 from 2023 to 2029.
The antiplatelet drug market is expected to propel during the forecast period owing to the increasing organic and inorganic growth taking place within the industry. Moreover, the market for generic is also at a rise thereby giving a boost to the generic antiplatelet drug manufacturers. The amount of money which the companies are spending towards research and development is also expected to contribute towards the revenue of the antiplatelet drugs market in the future. For instance in February 2017, PLx Pharma announced positive antiplatelet data for its Aspertec drug which was published in the Journal of the American College of Cardiology (JACC). Now researchers are concentrating on analyzing the pharmacodynamics and meta-analyses to determine whether one drug has an edge over other.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiplatelet Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Aspirin
Clopidogrel
Ticagrelor
Prasugrel
Dipyridamole
Ticlopidine
Abciximab
Tirofiban
Others
Segmentation by application
Hospitals
Clinic
Emergency Service Centers
Ambulatory Surgical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
The Medicines Company
AstraZeneca
The Medicines Company
Portola Pharmaceuticals
Bayer Pharmaceuticals
Bristol-Myers Squibb Company
Boehringer Ingelheim Pharmaceuticals
Alta Laboratories
Shandong Xinhua Pharmaceutical
Sanis Health
Syntex
Hoffmann La Roche
Teva
Sandoz Canada Incorporated
Pharmascience
Mylan Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antiplatelet Drugs market?
What factors are driving Antiplatelet Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiplatelet Drugs market opportunities vary by end market size?
How does Antiplatelet Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Antiplatelet Drugs Industry Forecast” looks at past sales and reviews total world Antiplatelet Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Antiplatelet Drugs sales for 2023 through 2029. With Antiplatelet Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiplatelet Drugs industry.
This Insight Report provides a comprehensive analysis of the global Antiplatelet Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiplatelet Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antiplatelet Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiplatelet Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiplatelet Drugs.
The global Antiplatelet Drugs market size is projected to grow from US$ 1410.4 million in 2022 to US$ 1914.2 million in 2029; it is expected to grow at a CAGR of 1914.2 from 2023 to 2029.
The antiplatelet drug market is expected to propel during the forecast period owing to the increasing organic and inorganic growth taking place within the industry. Moreover, the market for generic is also at a rise thereby giving a boost to the generic antiplatelet drug manufacturers. The amount of money which the companies are spending towards research and development is also expected to contribute towards the revenue of the antiplatelet drugs market in the future. For instance in February 2017, PLx Pharma announced positive antiplatelet data for its Aspertec drug which was published in the Journal of the American College of Cardiology (JACC). Now researchers are concentrating on analyzing the pharmacodynamics and meta-analyses to determine whether one drug has an edge over other.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiplatelet Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Aspirin
Clopidogrel
Ticagrelor
Prasugrel
Dipyridamole
Ticlopidine
Abciximab
Tirofiban
Others
Segmentation by application
Hospitals
Clinic
Emergency Service Centers
Ambulatory Surgical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
The Medicines Company
AstraZeneca
The Medicines Company
Portola Pharmaceuticals
Bayer Pharmaceuticals
Bristol-Myers Squibb Company
Boehringer Ingelheim Pharmaceuticals
Alta Laboratories
Shandong Xinhua Pharmaceutical
Sanis Health
Syntex
Hoffmann La Roche
Teva
Sandoz Canada Incorporated
Pharmascience
Mylan Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antiplatelet Drugs market?
What factors are driving Antiplatelet Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiplatelet Drugs market opportunities vary by end market size?
How does Antiplatelet Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antiplatelet Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Antiplatelet Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Antiplatelet Drugs by Country/Region, 2018, 2022 & 2029
2.2 Antiplatelet Drugs Segment by Type
2.2.1 Aspirin
2.2.2 Clopidogrel
2.2.3 Ticagrelor
2.2.4 Prasugrel
2.2.5 Dipyridamole
2.2.6 Ticlopidine
2.2.7 Abciximab
2.2.8 Tirofiban
2.2.9 Others
2.3 Antiplatelet Drugs Sales by Type
2.3.1 Global Antiplatelet Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Antiplatelet Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Antiplatelet Drugs Sale Price by Type (2018-2023)
2.4 Antiplatelet Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinic
2.4.3 Emergency Service Centers
2.4.4 Ambulatory Surgical Centers
2.4.5 Others
2.5 Antiplatelet Drugs Sales by Application
2.5.1 Global Antiplatelet Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Antiplatelet Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Antiplatelet Drugs Sale Price by Application (2018-2023)
3 Global Antiplatelet Drugs by Company
3.1 Global Antiplatelet Drugs Breakdown Data by Company
3.1.1 Global Antiplatelet Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Antiplatelet Drugs Sales Market Share by Company (2018-2023)
3.2 Global Antiplatelet Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Antiplatelet Drugs Revenue by Company (2018-2023)
3.2.2 Global Antiplatelet Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Antiplatelet Drugs Sale Price by Company
3.4 Key Manufacturers Antiplatelet Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antiplatelet Drugs Product Location Distribution
3.4.2 Players Antiplatelet Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Antiplatelet Drugs by Geographic Region
4.1 World Historic Antiplatelet Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Antiplatelet Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Antiplatelet Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Antiplatelet Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Antiplatelet Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Antiplatelet Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Antiplatelet Drugs Sales Growth
4.4 APAC Antiplatelet Drugs Sales Growth
4.5 Europe Antiplatelet Drugs Sales Growth
4.6 Middle East & Africa Antiplatelet Drugs Sales Growth
5 Americas
5.1 Americas Antiplatelet Drugs Sales by Country
5.1.1 Americas Antiplatelet Drugs Sales by Country (2018-2023)
5.1.2 Americas Antiplatelet Drugs Revenue by Country (2018-2023)
5.2 Americas Antiplatelet Drugs Sales by Type
5.3 Americas Antiplatelet Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antiplatelet Drugs Sales by Region
6.1.1 APAC Antiplatelet Drugs Sales by Region (2018-2023)
6.1.2 APAC Antiplatelet Drugs Revenue by Region (2018-2023)
6.2 APAC Antiplatelet Drugs Sales by Type
6.3 APAC Antiplatelet Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Antiplatelet Drugs by Country
7.1.1 Europe Antiplatelet Drugs Sales by Country (2018-2023)
7.1.2 Europe Antiplatelet Drugs Revenue by Country (2018-2023)
7.2 Europe Antiplatelet Drugs Sales by Type
7.3 Europe Antiplatelet Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antiplatelet Drugs by Country
8.1.1 Middle East & Africa Antiplatelet Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Antiplatelet Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Antiplatelet Drugs Sales by Type
8.3 Middle East & Africa Antiplatelet Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antiplatelet Drugs
10.3 Manufacturing Process Analysis of Antiplatelet Drugs
10.4 Industry Chain Structure of Antiplatelet Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antiplatelet Drugs Distributors
11.3 Antiplatelet Drugs Customer
12 World Forecast Review for Antiplatelet Drugs by Geographic Region
12.1 Global Antiplatelet Drugs Market Size Forecast by Region
12.1.1 Global Antiplatelet Drugs Forecast by Region (2024-2029)
12.1.2 Global Antiplatelet Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Antiplatelet Drugs Forecast by Type
12.7 Global Antiplatelet Drugs Forecast by Application
13 Key Players Analysis
13.1 The Medicines Company
13.1.1 The Medicines Company Company Information
13.1.2 The Medicines Company Antiplatelet Drugs Product Portfolios and Specifications
13.1.3 The Medicines Company Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 The Medicines Company Main Business Overview
13.1.5 The Medicines Company Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Antiplatelet Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 The Medicines Company
13.3.1 The Medicines Company Company Information
13.3.2 The Medicines Company Antiplatelet Drugs Product Portfolios and Specifications
13.3.3 The Medicines Company Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 The Medicines Company Main Business Overview
13.3.5 The Medicines Company Latest Developments
13.4 Portola Pharmaceuticals
13.4.1 Portola Pharmaceuticals Company Information
13.4.2 Portola Pharmaceuticals Antiplatelet Drugs Product Portfolios and Specifications
13.4.3 Portola Pharmaceuticals Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Portola Pharmaceuticals Main Business Overview
13.4.5 Portola Pharmaceuticals Latest Developments
13.5 Bayer Pharmaceuticals
13.5.1 Bayer Pharmaceuticals Company Information
13.5.2 Bayer Pharmaceuticals Antiplatelet Drugs Product Portfolios and Specifications
13.5.3 Bayer Pharmaceuticals Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bayer Pharmaceuticals Main Business Overview
13.5.5 Bayer Pharmaceuticals Latest Developments
13.6 Bristol-Myers Squibb Company
13.6.1 Bristol-Myers Squibb Company Company Information
13.6.2 Bristol-Myers Squibb Company Antiplatelet Drugs Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Company Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Company Main Business Overview
13.6.5 Bristol-Myers Squibb Company Latest Developments
13.7 Boehringer Ingelheim Pharmaceuticals
13.7.1 Boehringer Ingelheim Pharmaceuticals Company Information
13.7.2 Boehringer Ingelheim Pharmaceuticals Antiplatelet Drugs Product Portfolios and Specifications
13.7.3 Boehringer Ingelheim Pharmaceuticals Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Boehringer Ingelheim Pharmaceuticals Main Business Overview
13.7.5 Boehringer Ingelheim Pharmaceuticals Latest Developments
13.8 Alta Laboratories
13.8.1 Alta Laboratories Company Information
13.8.2 Alta Laboratories Antiplatelet Drugs Product Portfolios and Specifications
13.8.3 Alta Laboratories Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Alta Laboratories Main Business Overview
13.8.5 Alta Laboratories Latest Developments
13.9 Shandong Xinhua Pharmaceutical
13.9.1 Shandong Xinhua Pharmaceutical Company Information
13.9.2 Shandong Xinhua Pharmaceutical Antiplatelet Drugs Product Portfolios and Specifications
13.9.3 Shandong Xinhua Pharmaceutical Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Shandong Xinhua Pharmaceutical Main Business Overview
13.9.5 Shandong Xinhua Pharmaceutical Latest Developments
13.10 Sanis Health
13.10.1 Sanis Health Company Information
13.10.2 Sanis Health Antiplatelet Drugs Product Portfolios and Specifications
13.10.3 Sanis Health Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sanis Health Main Business Overview
13.10.5 Sanis Health Latest Developments
13.11 Syntex
13.11.1 Syntex Company Information
13.11.2 Syntex Antiplatelet Drugs Product Portfolios and Specifications
13.11.3 Syntex Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Syntex Main Business Overview
13.11.5 Syntex Latest Developments
13.12 Hoffmann La Roche
13.12.1 Hoffmann La Roche Company Information
13.12.2 Hoffmann La Roche Antiplatelet Drugs Product Portfolios and Specifications
13.12.3 Hoffmann La Roche Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Hoffmann La Roche Main Business Overview
13.12.5 Hoffmann La Roche Latest Developments
13.13 Teva
13.13.1 Teva Company Information
13.13.2 Teva Antiplatelet Drugs Product Portfolios and Specifications
13.13.3 Teva Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Teva Main Business Overview
13.13.5 Teva Latest Developments
13.14 Sandoz Canada Incorporated
13.14.1 Sandoz Canada Incorporated Company Information
13.14.2 Sandoz Canada Incorporated Antiplatelet Drugs Product Portfolios and Specifications
13.14.3 Sandoz Canada Incorporated Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sandoz Canada Incorporated Main Business Overview
13.14.5 Sandoz Canada Incorporated Latest Developments
13.15 Pharmascience
13.15.1 Pharmascience Company Information
13.15.2 Pharmascience Antiplatelet Drugs Product Portfolios and Specifications
13.15.3 Pharmascience Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Pharmascience Main Business Overview
13.15.5 Pharmascience Latest Developments
13.16 Mylan Pharmaceuticals
13.16.1 Mylan Pharmaceuticals Company Information
13.16.2 Mylan Pharmaceuticals Antiplatelet Drugs Product Portfolios and Specifications
13.16.3 Mylan Pharmaceuticals Antiplatelet Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Mylan Pharmaceuticals Main Business Overview
13.16.5 Mylan Pharmaceuticals Latest Developments
14 Research Findings and Conclusion